CYP2C9

The large PGx analysis might provide welcome data for those already supportive of genotyping in the context of warfarin, but will it convince detractors?

A study has demonstrated why dosing algorithms for warfarin have performed poorly in patients with African ancestry, especially in recent randomized clinical trials.

NEW YORK (GenomeWeb) – A new project spearheaded by Genome British Columbia and the BC Pharmacy Association (BCPhA) aims to assess whether pharmacists can drive adoption of genetic testing among doctors and help provide patients greater access to personalized medicine.

Originally published Nov. 22.
Doctors have been in a "should we or shouldn't we" conundrum with warfarin pharmacogenetic testing for years.

A new FDA draft guidance lays out the agency's thinking on what constitutes a companion diagnostic, as well as Rx/Dx situations in which it would accommodate the marketing of unapproved tests.

According to the agency, ParagonDx's ASR probes for gauging the presence of CYP2C9*2, CYP2C9*3, VKORC1 1173, VKORC1 3730 variants "are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body."

The FDA updated the labeling for warfarin on Jan. 22 to include PGx-guided dosing ranges. FDA's Lesko explained that the labeling provides dosing ranges in order to give doctors the flexibility to consider their patients clinical factors when determining the appropriate maintenance dose of the anticoagulant.

Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.